Levocarnitine Paediatric Aspire Pharma (Levocarnitine)

Levocarnitine is used to treat disorders of fatty‑acid metabolism and primary carnitine deficiency.

• Primary carnitine deficiency: restores intracellular carnitine levels to improve energy production.
• Secondary carnitine deficiency: supplements depleted carnitine stores in conditions such as renal dialysis or certain metabolic disorders.
• Fatty acid oxidation disorders: supports beta‑oxidation of long‑chain fatty acids, reducing metabolic crises in affected children.

• Levocarnitine acts as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane. By forming acyl‑carnitine complexes, it enables the fatty acids to enter the mitochondrial matrix where they undergo β‑oxidation, generating acetyl‑CoA for the citric acid cycle and ATP production. This restores normal fatty‑acid utilization in tissues with deficient endogenous carnitine.

Levocarnitine may be associated with several adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild stomach upset reported in some patients.
• Vomiting: occasional episodes, usually transient.
• Diarrhea: loose stools, generally self‑limiting.
• Abdominal discomfort: cramping or pain in the abdomen.
• Headache: mild headache without other neurological signs.
• Metallic taste: temporary alteration in taste perception.

Serious or Rare Side Effects

• Hypersensitivity reaction: rash, itching, or swelling indicating an allergic response.
• Anaphylaxis: rare severe allergic reaction requiring immediate medical attention.
• Severe muscle weakness: unexpected loss of muscle strength.
• Metabolic acidosis: rare disturbance in blood pH.
• Liver enzyme elevation: abnormal increase in hepatic transaminases.

When prescribing Levocarnitine, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess kidney performance and adjust use in severe impairment.
• Cardiac disease: monitor cardiac status as carnitine influences myocardial energy metabolism.
• Metabolic disorders: employ under specialist supervision for complex metabolic conditions.
• Pediatric dosing: follow specialist‑determined dosing regimens for children.
• Pregnancy: safety data are limited; weigh potential benefits against unknown risks.
• Store at room temperature: keep below 25 °C in the original packaging, protected from moisture.

Levocarnitine can interact with certain medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: may increase carnitine depletion, reducing therapeutic effect.
• Hemodialysis: can remove levocarnitine from circulation, necessitating supplemental dosing.
• Broad‑spectrum antibiotics (e.g., ceftriaxone): may alter gut flora and affect endogenous carnitine synthesis.

Moderate Interactions (Monitor Closely)

• Phenobarbital: induces hepatic enzymes that may increase levocarnitine metabolism.
• Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring.
• Thyroid hormone therapy: may modify carnitine metabolism, necessitating clinical observation.